Yves Bertrand

Suggest Changes
Learn More
BACKGROUND Previous reports have suggested that imatinib may increase cyclosporine exposure by CYP3A4 inhibition. However, the magnitude of this drug interaction remains unclear. At present,(More)
Allogeneic hematopoietic SCT (HSCT) appears to be an efficient tool to cure high-risk AML in first CR but the choice between BU-based or TBI-based conditioning regimens still remains controversial.(More)
We report French prospective experience with reduced-intensity conditioning–allo-SCT in 46 patients (median age: 15.5 years, 4.8–20.2) presenting high-risk AL (n=11), Hodgkin’s lymphoma (n=15) or(More)